<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04884542</url>
  </required_header>
  <id_info>
    <org_study_id>K-23</org_study_id>
    <nct_id>NCT04884542</nct_id>
  </id_info>
  <brief_title>Multigen Plus H Study</brief_title>
  <official_title>A Prospective, Post-marketing Study Evaluating Clinical and Radiographic Early Outcomes of Revision Total Knee Arthroplasty With Multigen Plus H.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Limacorporate S.p.a</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Limacorporate S.p.a</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the clinical, patient-reported, and radiographic outcomes&#xD;
      of a revision Total Knee Arthroplasty with Multigen Plus H.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional Knee Society Score (KSS)</measure>
    <time_frame>Month 24</time_frame>
    <description>Evaluation of the changes in the Functional Knee Society Score (KSS) after revision TKA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KOOS-ADL (Function in Daily Living subdomain)</measure>
    <time_frame>Month 24</time_frame>
    <description>Evaluation of the functional changes in the KOOS-ADL domain after revision TKA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Pain score</measure>
    <time_frame>Month 24</time_frame>
    <description>Evaluation of the changes in the VAS Pain score after revision TKA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survivorship of the implant</measure>
    <time_frame>Month 24</time_frame>
    <description>Kaplan-Meier estimate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic implant evaluation and stability assessment</measure>
    <time_frame>Month 24</time_frame>
    <description>Evaluation of progressive Radiolucent Lines after revision TKA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>Intra-operatively, Month 3, Month 12, and Month 24</time_frame>
    <description>Incidence, type, and severity of all the Adverse Events (AEs) occurred after revision TKA</description>
  </secondary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revision Total Knee Arthroplasty</intervention_name>
    <description>Total Knee Arthroplasty in case of failure of a previous operation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The subject population for this study includes adult subjects in whom the decision to&#xD;
        perform a revision Total Knee Arthroplasty with Multigen Plus H system must be taken prior&#xD;
        to, and independently from, the decision to include the subject into the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Given written informed consent approved by the reference Ethics Committee (EC)&#xD;
&#xD;
          -  Subjects in whom a decision has already been made to perform a revision Total Knee&#xD;
             Arthroplasty with Multigen Plus H system as per Indication For Use. The decision to&#xD;
             implant the Multigen Plus H system must be taken prior to, and independently from, the&#xD;
             decision to enrol the subject. This decision should be made in accordance with routine&#xD;
             standard of care at the study site.&#xD;
&#xD;
          -  Subject is able to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Subjects with any Multigen Plus system contraindication for use as reported in the&#xD;
             current Instruction For Use&#xD;
&#xD;
          -  Any clinically significant pathology based on the medical history that the&#xD;
             Investigator feels may affect the study evaluation&#xD;
&#xD;
          -  Female subjects who are pregnant, nursing, or planning a pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Federica Azzimonti</last_name>
    <phone>+39 377 5450940</phone>
    <email>federica.azzimonti@limacorporate.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabiana Pavan</last_name>
    <phone>+39 348 5816391</phone>
    <email>fabiana.pavan@limacorporate.com</email>
  </overall_contact_backup>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

